ABCL-185 Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Mosunetuzumab with polatuzumab vedotin (mosun-pola; investigational off-label use) in the phase Ib/II study (NCT03671018), demonstrated durable responses and manageable safety in pts with relapsed/refractory, transplant-ineligible LBCL. Present results for primary refractory (refr) or early relapse...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-09, Vol.24, p.S461-S461
Main Authors: Assouline, Sarit, Elizabeth Budde, Lihua, Chavez, Julio C., Diefenbach, Catherine S., Anne Dorritie, Kathleen, Ghosh, Nilanjan, Olszewski, Adam J., Lossos, Izidore S., Mehta, Amitkumar, Modi, Dipenkumar, Naik, Seema, Douglas Smith, Stephen, Makadia, Sneha, Pham, Song, Wu, Hao, Lee Batlevi, Connie, To, Iris, Wei, Michael C., Kamdar, Manali
Format: Article
Language:English
Subjects:
ABCL
antibody
bispecific
large B-cell lymphoma
relapsed/refractory
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mosunetuzumab with polatuzumab vedotin (mosun-pola; investigational off-label use) in the phase Ib/II study (NCT03671018), demonstrated durable responses and manageable safety in pts with relapsed/refractory, transplant-ineligible LBCL. Present results for primary refractory (refr) or early relapse (rel) subgroups from NCT03671018 after a median follow-up of 23.9 months. Pts with relapsed/refractory LBCL (diffuse LBCL not otherwise specified [NOS], high-grade B-cell lymphoma [HGBCL], transformed FL, and FL grade 3b) and who received ≥1 prior line of therapy (including an anti-CD20 antibody) were treated with mosun-pola. Refr defined as SD, PD, PR, or CR with relapse
ISSN:2152-2650
DOI:10.1016/S2152-2650(24)01494-0